Alessandro Rambaldi
0000-0002-3739-7502
Publication & Citation Trends
Publications
0 total
Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma
Cited by 0
Semantic Scholar
POSTER: ABCL-1093 Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical Update
Cited by 0
Semantic Scholar
ABCL-1093: Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical Update
Cited by 0
Semantic Scholar
POS0481 “Real World” Incidence and Characteristics of Immune Effector Cell–Associated Hemophagocytic Lymphohisticytosis: A GoCart Coalition Study on Behalf of the European Bone Marrow TraNsplantation (EBMT) Autoimmune Disease Working Party (ADWP), Cellular Therapy Working Party (CTIWP) and transplan
Cited by 1
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(355)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(293)
Chronic Myeloid Leukemia Treatments
(282)
Acute Lymphoblastic Leukemia research
(281)
Lymphoma Diagnosis and Treatment
(234)
Affiliations
University of Bergamo
Ontario Institute for Cancer Research
Goethe University Frankfurt
Roche (Switzerland)
University of Bern